Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study-Reference-Cited by-同舟云学术

Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study

Published:2018-09-11 Issue:11 Volume:45 Page:1337-1339
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Nakamura Yoshiyuki¹^ORCID,Fujisawa Yasuhiro¹^ORCID,Tanaka Ryota¹,Maruyama Hiroshi¹^ORCID,Ishitsuka Yosuke¹,Okiyama Naoko¹^ORCID,Watanabe Rei¹^ORCID,Fujimoto Manabu¹

Affiliation:

1. Department of Dermatology; Faculty of Medicine; University of Tsukuba; Tsukuba Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14637/fullpdf

Reference10 articles.

1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma;Hamid;Eur J Cancer,2017